Dyne Therapeutics, Inc. (DYN)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 4,500 | $78K |
| Open-market sale | 46 | 4,761,253 | $113.57M |
| Grant or award | 8 | 303,527 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
83 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jason P. Rhodes | Open-market sale | Common Stock | 3,136 | $18.00 | $56K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 6,241 | $18.00 | $112K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 61 | $18.00 | $1K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 2,466 | $18.00 | $44K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 3,056 | $18.03 | $55K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 6,081 | $18.03 | $110K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 60 | $18.03 | $1K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 2,403 | $18.03 | $43K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 21,926 | $18.18 | $399K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 43,621 | $18.18 | $793K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 428 | $18.18 | $8K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 17,244 | $18.18 | $313K | |
| David Charles Lubner | Gift | Common Stock | 53,625 | $0.00 | - | |
| Jason P. Rhodes | Open-market sale | Common Stock | 19,261 | $19.19 | $370K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 38,322 | $19.19 | $735K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 377 | $19.19 | $7K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 15,148 | $19.19 | $291K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 36,345 | $18.48 | $672K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 72,310 | $18.48 | $1.34M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 710 | $18.48 | $13K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 28,583 | $18.48 | $528K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 45,709 | $18.15 | $830K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 90,943 | $18.15 | $1.65M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 894 | $18.15 | $16K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 35,947 | $18.15 | $652K | |
| Dirk Kersten | Open-market sale | Common Stock | 8,300 | $20.01 | $166K | |
| Dirk Kersten | Open-market sale | Common Stock | 2,652 | $20.00 | $53K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 71,676 | $20.06 | $1.44M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 142,604 | $20.06 | $2.86M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 1,401 | $20.06 | $28K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 56,368 | $20.06 | $1.13M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 71,499 | $19.51 | $1.39M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 142,253 | $19.51 | $2.78M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 1,398 | $19.51 | $27K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 56,228 | $19.51 | $1.10M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 769 | $20.05 | $15K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 1,530 | $20.05 | $31K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 15 | $20.05 | $301 | |
| Jason P. Rhodes | Open-market sale | Common Stock | 605 | $20.05 | $12K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 75,866 | $19.68 | $1.49M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 150,942 | $19.68 | $2.97M | |
| Jason P. Rhodes | Open-market sale | Common Stock | 1,485 | $19.68 | $29K | |
| Jason P. Rhodes | Open-market sale | Common Stock | 59,663 | $19.68 | $1.17M | |
| Dirk Kersten | Open-market sale | Common Stock | 211,974 | $20.29 | $4.30M | |
| Dirk Kersten | Open-market sale | Common Stock | 125,274 | $20.07 | $2.51M | |
| Dirk Kersten | Open-market sale | Common Stock | 81,840 | $20.27 | $1.66M | |
| Dirk Kersten | Open-market sale | Common Stock | 11,116 | $21.10 | $235K | |
| Dirk Kersten | Open-market sale | Common Stock | 6,657 | $20.06 | $134K | |
| Erick Lucera - Officer | Open-market sale | Common Stock | 5,727 | $18.64 | $107K | |
| Brian S. Posner | Open-market purchase | Common Stock | 2,000 | $17.08 | $34K | |
| Brian S. Posner | Open-market purchase | Common Stock | 2,000 | $19.35 | $39K | |
| Dirk Kersten | Open-market sale | Common Stock | 129,672 | $19.52 | $2.53M | |
| Dirk Kersten | Open-market sale | Common Stock | 177,690 | $17.72 | $3.15M | |
| Dirk Kersten | Open-market sale | Common Stock | 9,482 | $18.21 | $173K | |
| Dirk Kersten | Open-market sale | Common Stock | 219,758 | $19.33 | $4.25M | |
| Dirk Kersten | Open-market sale | Common Stock | 281,858 | $19.80 | $5.58M | |
| Brian S. Posner | Open-market purchase | Common Stock | 3,000 | $15.06 | $45K | |
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 148 | $14.90 | $2K | |
| Douglas Kerr - Officer | Open-market sale | Common Stock | 904 | $14.90 | $13K | |
 John Cox - Officer | Open-market sale | Common Stock | 2,732 | $14.90 | $41K | |
| John Cox - Officer | Grant or award | Common Stock | 180,000 | $0.00 | - | |
| John Cox - Officer | Grant or award | Stock option (right to buy) | 285,000 | $0.00 | - | |
| Douglas Kerr - Officer | Grant or award | Common Stock | 85,000 | $0.00 | - | |
| Douglas Kerr - Officer | Grant or award | Stock option (right to buy) | 130,000 | $0.00 | - | |
| Johanna Friedl-Naderer - Officer | Grant or award | Common Stock | 60,000 | $0.00 | - | |
| Johanna Friedl-Naderer - Officer | Grant or award | Stock option (right to buy) | 90,000 | $0.00 | - | |
| Erick Lucera - Officer | Grant or award | Common Stock | 65,000 | $0.00 | - | |
| Erick Lucera - Officer | Grant or award | Stock Option (Right to Buy) | 105,000 | $0.00 | - | |
| Vikram Karnani | Grant or award | Stock option (right to buy) | 59,665 | $0.00 | - | |
| John Cox - Officer | Open-market sale | Common Stock | 2,662 | $20.72 | $55K | |
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 144 | $20.72 | $3K | |
| Douglas Kerr - Officer | Open-market sale | Common Stock | 880 | $20.72 | $18K | |
| Brian S. Posner | Grant or award | Stock option (right to buy) | 70,000 | $0.00 | - | |
| John Cox - Officer | Open-market sale | Common Stock | 2,640 | $13.41 | $35K | |
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 894 | $13.27 | $12K | |
| Johanna Friedl-Naderer - Officer | Open-market sale | Common Stock | 144 | $13.41 | $2K | |
| Douglas Kerr - Officer | Open-market sale | Common Stock | 3,552 | $13.27 | $47K | |
| Douglas Kerr - Officer | Open-market sale | Common Stock | 873 | $13.41 | $12K | |
| John Cox - Officer | Grant or award | Stock option (right to buy) | 197,285 | $0.00 | - | |
| Johanna Friedl-Naderer - Officer | Grant or award | Stock option (right to buy) | 51,255 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Atlas Venture Opportunity Fund I, LP | Shareholder | 322,465 | $8.37M | View on EDGAR | |
| Atlas Venture Fund XI, LP | Shareholder | 1,359,674 | $35.30M | View on EDGAR | |
| Atlas Venture Opportunity Fund II, LP | Shareholder | 478,377 | $12.42M | View on EDGAR |
Dyne Therapeutics, Inc. (DYN) had 24 insider filings in the last 90 days, with the most recent on 2026-08-17. The full record for DYN runs to 83 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of DYN were filed in the last 90 days, totaling $78K.
46 insider sales of DYN were filed in the last 90 days, totaling $113.57M.
This page tracks DYN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DYN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
